Kaakinen Timo, Alaoja Hanna, Heikkinen Janne, Dahlbacka Sebastian, Laurila Päivi, Kiviluoma Kai, Salomäki Timo, Tuominen Hannu, Ohtonen Pasi, Biancari Fausto, Juvonen Tatu
Department of Surgery, Oulu University Hospital, University of Oulu, Oulu, Finland.
Ann Thorac Surg. 2006 Jan;81(1):183-90. doi: 10.1016/j.athoracsur.2005.07.017.
Hypertonic saline dextran (HSD) has been shown to have neuroprotective properties. In the present study we have assessed its potential neuroprotective efficacy in the setting of hypothermic circulatory arrest in a surviving porcine model.
Twenty-four pigs were randomized to receive two 5-minute intravenous infusions (4 mL/kg) of either HSD (7.5 % saline, 6% dextran 70) or normal saline immediately after and 4 hours after a 75-minute period of hypothermic circulatory arrest at a brain temperature of 18 degrees C.
The 7-day survival was 75% in the HSD group and 66% in the control group (p > 0.9). Brain total histopathologic score was lower in the HSD group (p = 0.01). Postoperative behavioral scores were higher in the HSD group on the second day after surgery (p = 0.03). Intracranial pressure was lower in the HSD group from 45 minutes to 8 hours after hypothermic circulatory arrest (p = 0.03). Cerebral perfusion pressure was higher in the HSD group from 45 minutes to 3 hours after hypothermic circulatory arrest (p = 0.06). Brain lactate concentration was lower in the HSD group when compared with controls (p = 0.05). Furthermore, brain glucose levels tended to be higher and brain lactate-pyruvate ratio and lactate-glucose ratio were lower in the HSD group. Brain tissue oxygen partial pressures were somewhat higher in the HSD group (p = 0.08).
The use of HSD in experimental hypothermic circulatory arrest is associated with significantly better neurologic recovery, better histopathology, lower intracranial pressure, higher cerebral perfusion pressure, and better preservation of brain metabolism.
高渗盐水右旋糖酐(HSD)已被证明具有神经保护特性。在本研究中,我们评估了其在存活猪模型的低温循环骤停情况下潜在的神经保护效果。
24头猪被随机分为两组,在脑温为18摄氏度的75分钟低温循环骤停后立即及4小时后,分别接受两次5分钟的静脉输注(4毫升/千克),一组输注HSD(7.5%盐水,6%右旋糖酐70),另一组输注生理盐水。
HSD组7天生存率为75%,对照组为66%(p>0.9)。HSD组脑总组织病理学评分较低(p = 0.01)。术后第二天HSD组的行为评分较高(p = 0.03)。低温循环骤停后45分钟至8小时,HSD组颅内压较低(p = 0.03)。低温循环骤停后45分钟至3小时,HSD组脑灌注压较高(p = 0.06)。与对照组相比,HSD组脑乳酸浓度较低(p = 0.05)。此外,HSD组脑葡萄糖水平倾向于较高,脑乳酸 - 丙酮酸比值和乳酸 - 葡萄糖比值较低。HSD组脑组织氧分压略高(p = 0.08)。
在实验性低温循环骤停中使用HSD与显著更好的神经功能恢复、更好的组织病理学、更低的颅内压、更高的脑灌注压以及更好的脑代谢保存相关。